Compare PLX & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLX | WIA |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 189.4M |
| IPO Year | 1996 | N/A |
| Metric | PLX | WIA |
|---|---|---|
| Price | $1.98 | $8.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 767.9K | 58.2K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.29% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $7.95 |
| 52 Week High | $3.19 | $8.54 |
| Indicator | PLX | WIA |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 44.52 |
| Support Level | $1.87 | $8.07 |
| Resistance Level | $2.15 | $8.24 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 31.40 | 21.43 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.